Vcanbio Cell & Gene Engineering Corp., Ltd.SSE: 600645

(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Extension of the Raised Funds Investment Project "Development of Tumor Marker Diagnostic Reagents"

· Issued by Vcanbio Cell & Gene Engineering Corp., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 600645 · · 4 pages · Chinese

Summary by 6ix AI

The filing details the reasons for the delay, including challenges faced during clinical trials due to public health events and new regulatory requirements. The company assures that the project's feasibility remains unchanged and that the extension will not adversely affect its normal operations. The board approved the extension without needing shareholder approval, and an independent financial advisor confirmed the decision's compliance with regulations.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/600645vcanbio-cell-and-gene-engineering-corp-ltdannouncement-on-extension-of-the-raised-funds-investment-project-development-of-tumor-marker-diagnostic-reagents

Release

Announcement on Extension of the Raised Funds Investment Project "Development of Tumor Marker Diagnostic Reagents"

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Vcanbio Cell & Gene Engineering Corp., Ltd. on 6ix

Story so far

Earlier from Vcanbio Cell & Gene Engineering

Later from Vcanbio Cell & Gene Engineering

All Vcanbio Cell & Gene Engineering news releases